Corbus intends to use the net proceeds of the proposed underwritten offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes. Jefferies is acting as sole book-running manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRBP:
- Corbus Pharmaceuticals Announces Proposed Public Offering
- Corbus Pharmaceuticals Raises $16.8 Million from Stock Sale
- Biotech Alert: Searches spiking for these stocks today
- Corbus Pharmaceuticals price target raised to $51 from $20 at Oppenheimer
- Corbus Pharmaceuticals’ Promising Phase 1 Cancer Trial Results
